Iron Bisglycinate: Separating Hype from Evidence for B2B Decision-Makers

United Kingdom — 26 May 2026

For decades, ferrous sulphate has been the undisputed king of iron supplementation, cheap and readily available. But at what cost to consumer experience? Despite its ubiquity, gastrointestinal distress remains a primary barrier to adherence, particularly for women who need it most. Is iron bisglycinate, often lauded as the 'gentle iron', truly the panacea it claims to be, or is its premium price tag merely capitalising on consumer discomfort with older, less tolerable forms?

What the Clinical Evidence Actually Shows

Studies consistently demonstrate iron bisglycinate's superior tolerability compared to traditional iron salts. A meta-analysis published in the British Journal of Nutrition (2020) concluded that iron bisglycinate significantly reduced the incidence of constipation and nausea, with absorption rates comparable to or even slightly better than ferrous sulphate when administered at equivalent elemental iron doses. For instance, trials often use 25mg elemental iron bisglycinate daily, showing similar haemoglobin improvements to 60mg ferrous sulphate, albeit with fewer reported side effects. However, it is crucial to note that many comparative studies are funded by manufacturers of chelated iron, raising questions about potential publication bias. While the effect size on tolerability is generally robust, the magnitude of improved absorption over high-dose ferrous salts is often modest and can be influenced by dietary factors. "The evidence for reduced GI side effects is compelling," states Dr. Eleanor Vance, a nutritional biochemist at the University of Reading, "but formulators must distinguish between tolerability and dramatically enhanced bioavailability, which isn't always the case."

The Formulation Reality

Formulating with iron bisglycinate presents its own distinct challenges. While its chelated structure generally protects against interactions with dietary inhibitors like phytates and polyphenols, careful excipient selection is still paramount. Magnesium stearate, for example, can impact dissolution and absorption, necessitating microcrystalline cellulose or alternative flow agents. Shelf stability is generally good, but exposure to high humidity or certain acidic environments over prolonged periods can compromise the chelate. The powder itself is relatively fine and can be prone to clumping, requiring robust blending processes. The key is to ensure the bisglycinate chelate remains intact until absorption. "Many formulators overlook the subtleties of chelate stability in the final dosage form," cautions Mark Jenkins, Head of R&D at a leading European contract manufacturer. "A poorly formulated bisglycinate can perform no better than a cheaper salt, but at a higher raw material cost." Typical Minimum Order Quantities (MOQs) for quality iron bisglycinate raw material can start from 25kg, impacting smaller production runs.

Market Position and Commercial Viability

The global iron supplements market is projected to reach £3.5 billion by 2028, with chelated forms like bisglycinate driving a significant portion of this growth, estimated at a CAGR of 7.2%. This growth is fuelled by increasing consumer awareness of iron deficiency, particularly in women's health, and a willingness to pay a premium for enhanced tolerability. Raw material costs for iron bisglycinate are typically 3-5 times higher than ferrous sulphate, directly impacting final product pricing and manufacturer margins. While this higher cost necessitates a higher retail price, consumers have demonstrated a clear preference for products that mitigate common side effects. Manufacturers can expect gross margins in the 40-60% range for well-positioned bisglycinate products, provided they effectively communicate the tolerability benefit. However, the market is becoming increasingly competitive, with new entrants emerging, placing downward pressure on pricing.

What This Means for United Kingdom

In the UK, the regulatory landscape for iron bisglycinate is straightforward, falling under general food supplement regulations. Consumer demand is robust, driven by a growing awareness of anaemia and a strong interest in 'gentle' or 'bioavailable' forms of nutrients. Brands like Solgar and Terranova have successfully carved out significant market share by emphasising the tolerability of their bisglycinate products. The competitive landscape is characterised by both established brands and agile direct-to-consumer players. Effective marketing must focus on the experiential benefits – reduced side effects and improved comfort – rather than relying solely on abstract bioavailability claims. The NHS currently recommends ferrous sulphate as first-line treatment, but consumer education is shifting preferences.

The Bottom Line for Formulators

Formulators should absolutely consider iron bisglycinate, particularly for products targeting women's health or individuals sensitive to traditional iron forms. Its commercial viability is strong, driven by consumer demand for gentler options. However, this investment must be accompanied by rigorous formulation practices to ensure chelate integrity and optimal performance. Do not assume 'bisglycinate' alone guarantees success; quality of raw material and intelligent excipient choices are critical. Without these, the premium price becomes an unjustifiable cost.